B-1211, 401 Yangcheon-ro
Gangseo-gu
Seoul 07528
South Korea
82 2 322 1687
https://www.eyegene.co.kr
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 47
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Won-Il Yoo | Chief Executive Officer | N/A | N/A | N/A |
Dr. Yang-Je Cho | Co-Founder and Chief Technology Officer | N/A | N/A | N/A |
Soobeom Lee | Chief Financial Officer | N/A | N/A | N/A |
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company's products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculosis vaccine; and EG-HPV that has completed Phase I clinical trial for the treatment of cervical cancer. It also offers EG-Vac for the treatment of immune adjuvant; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-HZ, which has completes phase I trials for the treatment of herpes zoster. In addition, the company provides vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
EyeGene Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.